CD4(+) T Cells Prevent Spontaneous Experimental Autoimmune Encephalomyelitis in Anti-myelin Basic Protein T Cell Receptor Transgenic Mice
Overview
General Medicine
Authors
Affiliations
Autoimmune diseases result from a failure of tolerance. Although many self-reactive T cells are present in animals and humans, their activation appears to be prevented normally by regulatory T cells. In this study, we show that regulatory CD4(+) T cells do protect mice against the spontaneous occurrence of experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis. Anti-myelin basic protein (MBP) TCR transgenic mice (T/R+) do not spontaneously develop EAE although many self-reactive T cells are present in their thymi and peripheral lymphoid organs. However, the disease develops in all crosses of T/R+ mice with recombination-activating gene (RAG)-1 knockout mice in which transgenic TCR-expressing cells are the only lymphocytes present (T/R- mice). In this study, crosses of T/R+ mice with mice deficient for B cells, CD8(+) T cells, NK1.1 CD4(+) T (NKT) cells, gamma/delta T cells, or alpha/beta T cells indicated that alpha/beta CD4(+) T cells were the only cell population capable of controlling the self-reactive T cells. To confirm the protective role of CD4(+) T cells, we performed adoptive transfer experiments. CD4(+) T cells purified from thymi or lymph nodes of normal mice prevented the occurrence of spontaneous EAE in T/R- mice. To achieve full protection, the cells had to be transferred before the recipient mice manifested any symptoms of the disease. Transfer of CD4(+) T cells after the appearance of symptoms of EAE had no protective effect. These results indicate that at least some CD4(+) T cells have a regulatory function that prevent the activation of self-reactive T cells.
Zarobkiewicz M, Morawska I, Michalski A, Rolinski J, Bojarska-Junak A Int J Mol Sci. 2021; 22(17).
PMID: 34502425 PMC: 8431671. DOI: 10.3390/ijms22179520.
Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease.
Matejuk A, Vandenbark A, Offner H Front Neurol. 2021; 12:672455.
PMID: 34135852 PMC: 8200536. DOI: 10.3389/fneur.2021.672455.
Yeola A, Doss P, Baillargeon J, Akbar I, Mailhot B, Balood M Front Immunol. 2020; 10:3115.
PMID: 32010149 PMC: 6974510. DOI: 10.3389/fimmu.2019.03115.
Wang L, Winnewisser J, Federle C, Jessberger G, Nave K, Werner H Front Immunol. 2017; 8:1511.
PMID: 29170668 PMC: 5684123. DOI: 10.3389/fimmu.2017.01511.
pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation.
Duraes F, Lippens C, Steinbach K, Dubrot J, Brighouse D, Bendriss-Vermare N J Autoimmun. 2015; 67:8-18.
PMID: 26341385 PMC: 4758828. DOI: 10.1016/j.jaut.2015.08.014.